7 results
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
- Pharmacology ... Summary Mechanisms ... • Euglycemic diabetic ... #Pharmacology # ... Summary #DM2 #diabetes
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... Summary Mechanisms ... not definitively cause ... #Pharmacology # ... Summary #DM2 #diabetes
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... Summary Mechanisms ... agent • Does not cause ... #Summary #DM2 # ... diabetes #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Medication Guide Classes ... α-glucosidase inhibitor ... 0.3-0.6 units/kg ... #Mellitus #DM2 ... #pharmacology #
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
class of anti-diabetic ... kidney), which causes ... the patient to ... #Pharmacology # ... Medications #DM2
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Summary Mechanisms ... side effects (e.g ... not definitively cause ... #Summary #DM2 # ... diabetes #endocrinology
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
Anthracyclines cause ... HER2 agents cause ... discussion with the patient ... hypertension, diabetes ... cardiology #oncology #pharmacology